Valuation: Forte Biosciences, Inc.

Market Cap 1.87B 1.64B 1.53B 1.41B 2.64B 179B 2.68B 18.16B 7.11B 88.74B 7.03B 6.88B 307B P/E 2026 *
-19.3x
P/E 2027 * -18.8x
Enterprise Value 1.87B 1.64B 1.53B 1.41B 2.64B 179B 2.68B 18.16B 7.11B 88.74B 7.03B 6.88B 307B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.86%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Forte Biosciences, Inc.

1 day+0.20%
1 week+51.09%
Current month+260.71%
1 month+264.48%
3 months+190.51%
6 months+156.78%
Current year+181.08%
1 week 54.26
Extreme 54.264
76.68
1 month 19.95
Extreme 19.95
76.68
Current year 15.51
Extreme 15.51
76.68
1 year 9.1
Extreme 9.1
76.68
3 years 4.11
Extreme 4.11
76.68
5 years 4.11
Extreme 4.11
786.75
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2018
Director of Finance/CFO 59 01/03/2020
Chief Operating Officer - 01/10/2020
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 01/06/2020
Director/Board Member 79 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
7/1/26 A Fiscal year

Chief Executive Officer

2,598 0.0127%
7/1/26 A Fiscal year

Chief Financial Officer

884 0.0043%
6/16/26 A Free

Chief Executive Officer

500,000 2.4415%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%+51.09%+559.07%+203.56% 1.87B
-0.47%+1.27%+49.30%+68.05% 55.01B
-1.32%-2.71%+34.27%+77.57% 54.24B
+1.49%+0.13%-18.03%-13.94% 23.38B
-0.57%-4.13%+2.34%+387.73% 22.57B
+2.07%+1.39%+17.20%-10.70% 20.19B
-0.39%-0.52%+29.58%-31.79% 17.86B
-2.14%-3.75%+26.23%+558.64% 15.5B
-6.69%-5.11%+169.13%+304.89% 14.2B
+1.25%+0.69%+27.30%+184.69% 14.2B
Average -0.66%+4.51%+89.64%+172.87% 23.9B
Weighted average by Cap. -0.64%-0.12%+38.99%+132.14%

Financials

2026 *2027 *
Net sales - -
Net income -91.11M -79.96M -74.46M -68.48M -128M -8.7B -131M -883M -346M -4.32B -342M -335M -14.91B -107M -94.26M -87.77M -80.73M -151M -10.26B -154M -1.04B -408M -5.09B -403M -395M -17.58B
Net Debt - -
Logo Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
22
Date Price Change Volume
28/07/26 $76.65 +0.20% 2,571,079
27/07/26 $76.50 +39.65% 17,545,448
24/07/26 $54.78 -8.24% 575,893
23/07/26 $59.70 +5.42% 752,162
22/07/26 $56.63 +11.63% 530,808
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
76.65USD
Average target price
73.80USD
Spread / Average Target
-3.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock